Medication for Addiction Treatment During COVID-19
As overdose rates rise, we need addiction treatment in hospitals now more than ever. This guidance outlines how to implement medication for addiction treatment (MAT) during predicted COVID-19 surges.
New HHS Practice Guidelines
Here’s the most important takeaway of the “HHS Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder”: All prescribers with a valid state license and DEA can register for an X wavier without mandatory training.
Blueprint for Hospital Opioid Use Disorder Treatment
This comprehensive resource is scalable for any health system, based on our model implemented at diverse sites that demonstrate feasibility at large and small, public and private, urban, and rural hospitals.
Explore our collection of resources developed by an interdisciplinary team based on published evidence, best practices from the field and expert opinion.
Learn more about how the implementation of medication for addiction treatment (MAT) from the hospital setting can save tens of thousands of lives.